(P 123) OFF-LABEL DENOSUMAB IN LOCALLY AGGRESSIVE BENIGN BONE TUMORS OTHER THAN GIANT CELL TUMOR OF BONE.

Objective: This analysis aims to evaluate the evidence supporting the off-label use of denosumab in the management of locally aggressive benign bone tumors, with a focus on clinical outcomes, the potential for omitting further treatment, and the safety profile.

Methods: A retrospective analysis of 14 patients treated with denosumab. Tumor types studied included ABCs, osteoblastoma, chondroblastoma, fibrous dysplasia of bone, epithelioid hemangioma, and desmoplastic fibroma. The median age of patients treated was 24 years (range 16-47), and the median time of observation was 15 months.

Results: The median of denosumab injections was 10 (range 8-18), and the median time of treatment was 10 months (range 5-21). Denosumab has shown consistent efficacy in controlling disease and reducing pain, particularly in anatomically challenging locations. The most prominent radiological improvement was noted in ABCs. Only one patient was referred for subsequent treatment.

Conclusion: Off-label denosumab use represents an effective option in the multidisciplinary management of select benign but locally aggressive bone tumors. Optimal treatment duration, and recurrence risk warrant further investigation through prospective trials.